In 2007, Dr. Stephen Nissan, a cardiologist at the Cleveland Clinic, published an article in the New England Journal of Medicine that found a 43% increased chance of heart attack for patients taking a diabetes drug called Avandia. Nissan was one among many critics of the drug, which has since been pulled from the market. GlaxoSmithKline, the manufacturers of the drug, will pay a $90 million settlement fee, to be divided amongst 37 states and the District of Columbia, under allegations that they knew of the risks for four years, but fought to keep them from the public.
These prospects have some gray hair, and some assets.
The typical enrollee had a monthly out-of-pocket cost of $47 or lower.
The review rules will apply when the U.S. insurer has sensitive information about 1 million or more people.
Sponsored by Cetera Financial Group
Do you know the difference between client experience and customer service? The answer is crucial.
Sponsored by T. Rowe Price Investment Services, Inc.
The “reflation trade” appears real, but risks are still elevated.
Don’t miss crucial news and insights you need to make informed investment advisory decisions. Join ThinkAdvisor.com now!
- Free unlimited access to ThinkAdvisor.com which provides advisors, like you, with comprehensive coverage of the products, services and trends necessary to guide your clients in making critical wealth, health and life decisions.
- Exclusive discounts on ALM and ThinkAdvisor events.
- Access to other award-winning ALM websites including TreasuryandRisk.com and Law.com.
Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.